Second | 合法藥品大搜索

由 JA Burger 著作 · 2019 · 被引用 12 次 — BTK inhibitors, especially ibrutinib, have revolutionized the therapy of CLL, MCL and other B cell malignancies over the past few years, which is ... Read More

由 A Aalipour 著作 · 2014 · 被引用 62 次 — This encouraging preclinical framework has made BTK inhibition a rich field in pharmacology with several small molecule inhibitors in development including LFM- ... Read More

2020年1月7日 — What are Bruton Tyrosine Kinase (BTK) Inhibitors? ... Bruton Tyrosine Kinase (​BTK) inhibitors inhibit the enzyme BTK, which is a crucial part of the ... Read More

BTK inhibitors[edit] · Evobrutinib for multiple sclerosis. · ABBV-105 for systemic lupus erythematosus (SLE) · Fenebrutinib (GDC-0853, RG7845) for rheumatoid ... Read More

2019年9月30日 — 至於不適合移植的患者，新一代的BTK 抑制劑是最有效的單一治療藥物；另外亦可以依據患者 ... A New Therapeutic Option for MCL: BTK Inhibitor. Read More

由 T Wen 著作 · 2021 · 被引用 13 次 — Ibrutinib is the first-in-class BTK inhibitor and has been approved in more than 80 countries. The FDA has approved ibrutinib for CLL/SLL, WM, R/ ... Read More

Oral Btk inhibitors (ibrutinib) have been approved for treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia who have received at least ... Read More

2020年8月16日 — The first-generation BTK inhibitor ibrutinib (Imbruvica) came to market in 2013, when it was approved by the FDA to treat adult patients with ... Read More

由 HY Estupiñán 著作 · 2021 · 被引用 4 次 — Ibrutinib (Imbruvica®), the first-in-class BTK inhibitor (BTKi), is an irreversible binder, which has revolutionized the therapeutic landscape for B- ... Read More